- Home
- JGH vs CRMD Comparison
JGH vs CRMD Comparison
Compare JGH & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JGH
- CRMD
- Stock Information
- Founded
- JGH 2014
- CRMD 2006
- Country
- JGH United States
- CRMD United States
- Employees
- JGH N/A
- CRMD N/A
- Industry
- JGH Investment Managers
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- JGH Finance
- CRMD Health Care
- Exchange
- JGH Nasdaq
- CRMD Nasdaq
- Market Cap
- JGH 306.4M
- CRMD 925.6M
- IPO Year
- JGH N/A
- CRMD 2010
- Fundamental
- Price
- JGH $13.60
- CRMD $11.12
- Analyst Decision
- JGH
- CRMD Strong Buy
- Analyst Count
- JGH 0
- CRMD 8
- Target Price
- JGH N/A
- CRMD $17.57
- AVG Volume (30 Days)
- JGH 73.9K
- CRMD 4.6M
- Earning Date
- JGH 01-01-0001
- CRMD 10-29-2025
- Dividend Yield
- JGH 9.85%
- CRMD N/A
- EPS Growth
- JGH N/A
- CRMD N/A
- EPS
- JGH N/A
- CRMD 0.79
- Revenue
- JGH N/A
- CRMD $121,484,498.00
- Revenue This Year
- JGH N/A
- CRMD $404.81
- Revenue Next Year
- JGH N/A
- CRMD $56.11
- P/E Ratio
- JGH N/A
- CRMD $14.00
- Revenue Growth
- JGH N/A
- CRMD 14970.29
- 52 Week Low
- JGH $10.36
- CRMD $5.60
- 52 Week High
- JGH $12.85
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- JGH 59.68
- CRMD 34.64
- Support Level
- JGH $13.48
- CRMD $12.73
- Resistance Level
- JGH $13.64
- CRMD $13.83
- Average True Range (ATR)
- JGH 0.12
- CRMD 0.81
- MACD
- JGH -0.01
- CRMD -0.30
- Stochastic Oscillator
- JGH 80.00
- CRMD 0.90
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.